Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review
Author:
Publisher
Springer Science and Business Media LLC
Subject
Nephrology
Link
http://link.springer.com/article/10.1186/1471-2369-14-84/fulltext.html
Reference32 articles.
1. Herrmann E, Bierer S, Wulfing C: Update on systemic therapies of metastatic renal cell carcinoma. World J Urol. 2010, 28 (3): 303-309. 10.1007/s00345-010-0519-5.
2. Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE: Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005, 48 (1): 77-81. 10.1016/j.eururo.2005.03.004. discussion 81–72
3. Athar U, Gentile TC: Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008, 15 (2): 3954-3966.
4. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005, 23 (12): 2763-2771.
5. Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol. 2004, 22 (24): 4991-5004. 10.1200/JCO.2004.05.061.
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series;Clinical Journal of Gastroenterology;2024-03-19
2. Case report: Successful treatment of a patient undergoing haemodialysis with multifocal hepatocellular carcinoma using atezolizumab and bevacizumab;Frontiers in Oncology;2024-01-04
3. 血液透析中の肝細胞癌患者に対しアテゾリズマブ＋ベバシズマブ併用療法が可能であった一例;Kanzo;2023-12-01
4. Approach to Special Populations with Advanced Renal Cell Carcinoma;Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma;2023
5. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function;Cancer Chemotherapy and Pharmacology;2021-03-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3